First Transdermal Testosterone Gel to Significantly Increase Sexual Activity In Surgically Menopausal Women
November 01 2004 - 6:00AM
PR Newswire (US)
First Transdermal Testosterone Gel to Significantly Increase Sexual
Activity In Surgically Menopausal Women BioSante's LibiGel(TM)
Shows 238% Increase in Frequency Of Satisfying Sexual Events,
According to Data at ISSWSH LINCOLNSHIRE, Ill., Nov. 1
/PRNewswire-FirstCall/ -- BioSante Pharmaceuticals, Inc. (AMEX:BPA)
today announced the presentation of new Phase II clinical data on
LibiGel(TM) (transdermal testosterone gel) at the International
Society for the Study of Women's Sexual Health (ISSWSH) Annual
Meeting in Atlanta (October 28-31). Results show the ability of
LibiGel to significantly increase the number of satisfying sexual
events experienced by surgically menopausal women with female
sexual dysfunction (FSD). BioSante's Phase II study assessed the
safety and efficacy of LibiGel in the treatment of surgically
menopausal women with FSD. Results showed that LibiGel 150 mcg per
day significantly increased the number of satisfying sexual events
by 238 percent versus baseline (from 2.1 events per month at
baseline to 7.1 events during month three; p
Biosante Pharma (AMEX:BPA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biosante Pharma (AMEX:BPA)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Biosante Pharmaceuticals (American Stock Exchange): 0 recent articles
More Biosante Pharmaceuticals, News Articles